BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29339403)

  • 21. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
    Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
    BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
    Kipp D; H Wei A
    Future Oncol; 2021 Jul; 17(20):2563-2571. PubMed ID: 33769069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience.
    Onec B; Okutan H; Albayrak M; Can ES; Aslan V; Koluman BU; Kosemehmetoglu OS; Albayrak A
    J Cancer Res Ther; 2018; 14(5):1105-1111. PubMed ID: 30197357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution.
    Nomani L; Cook JR; Rogers HJ
    Int J Lab Hematol; 2019 Aug; 41(4):e86-e88. PubMed ID: 30707502
    [No Abstract]   [Full Text] [Related]  

  • 26. Concise drug review: azacitidine and decitabine.
    Derissen EJ; Beijnen JH; Schellens JH
    Oncologist; 2013; 18(5):619-24. PubMed ID: 23671007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
    Wang H; Bai J; Pei Z; Zhang B; Wang J; Lian X; Song Q
    Medicine (Baltimore); 2020 Nov; 99(47):e23265. PubMed ID: 33217852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
    Choi M; Song J; Bui CN; Ma E; Chai X; Yin L; Betts KA; Kapustyan T; Montez M; LeBlanc TW
    J Manag Care Spec Pharm; 2022 Sep; 28(9):980-988. PubMed ID: 35708343
    [No Abstract]   [Full Text] [Related]  

  • 29. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
    Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
    Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
    Abaza Y; Kantarjian H; Alwash Y; Borthakur G; Champlin R; Kadia T; Garcia-Manero G; Daver N; Ravandi F; Verstovsek S; Burger J; Estrov Z; Ohanian M; Lim M; Pemmaraju N; Jabbour E; Cortes J
    Am J Hematol; 2020 Nov; 95(11):1288-1295. PubMed ID: 32681739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
    Ai H; Wei XD; Yin QS; Wang P; Mi RH; Yuan FF; Chen L; Song YP
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):606-609. PubMed ID: 28789495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report.
    Lampkin BC; Woods WG; Buckley JD; Hammond GD
    Haematol Blood Transfus; 1990; 33():210-4. PubMed ID: 1691130
    [No Abstract]   [Full Text] [Related]  

  • 33. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
    Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
    Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
    Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
    Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
    [No Abstract]   [Full Text] [Related]  

  • 35. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
    Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
    Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study.
    Steuber CP; Holbrook T; Camitta B; Land VJ; Sexauer C; Krischer J
    Invest New Drugs; 1991 May; 9(2):181-4. PubMed ID: 1714886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
    Erba HP
    Leuk Res; 2015 Feb; 39(2):183-91. PubMed ID: 25577399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Yang D; Pillai R; Sanchez JF; Mei M; Aribi A; Ali H; Sandhu K; Al Malki MM; Salhotra A; Khaled S; Sun W; O'Donnell M; Snyder D; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Am J Hematol; 2019 Oct; 94(10):E253-E255. PubMed ID: 31259427
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study.
    Steuber CP; Krischer J; Holbrook T; Camitta B; Land V; Sexauer C; Mahoney D; Weinstein H
    J Clin Oncol; 1996 May; 14(5):1521-5. PubMed ID: 8622066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.